HRs for adverse events according to increasing levels of AGEs and sRAGE
| . | . | sRAGE (log scale) (per 1 unit*) . | Laboratory AGE value (per 100 RFU/mg protein*) . | ||
|---|---|---|---|---|---|
| Model . | Outcome . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| 1 | All-cause death | 1.20 (1.09–1.32) | 0.0002 | 1.05 (0.97–1.14) | 0.2193 |
| Major cardiovascular events | 1.16 (1.05–1.29) | 0.0038 | 1.06 (0.98–1.15) | 0.1262 | |
| New or worsening nephropathy | 1.43 (1.23–1.67) | <0.0001 | 1.25 (1.12–1.38) | <0.0001 | |
| 2 | All-cause death | 1.17 (1.06–1.29) | 0.0015 | 1.00 (0.91–1.09) | 0.9474 |
| Major cardiovascular events | 1.14 (1.02–1.26) | 0.0158 | 1.02 (0.93–1.11) | 0.7392 | |
| New or worsening nephropathy | 1.39 (1.19–1.63) | <0.0001 | 1.21 (1.08–1.35) | 0.0009 | |
| 3 | All-cause death | 1.11 (1.00–1.22) | 0.0451 | 0.97 (0.89–1.06) | 0.5382 |
| Major cardiovascular events | 1.08 (0.97–1.21) | 0.1471 | 1.02 (0.93–1.12) | 0.7121 | |
| New or worsening nephropathy | 1.20 (1.02–1.41) | 0.0316 | 1.21 (1.08–1.36) | 0.0013 | |
| 4 | All-cause death | 1.17 (1.06–1.29) | 0.0013 | 0.97 (0.89–1.06) | 0.5522 |
| Major cardiovascular events | 1.15 (1.03–1.27) | 0.0102 | 0.99 (0.91–1.09) | 0.8881 | |
| New or worsening nephropathy | 1.34 (1.15–1.57) | 0.0002 | 1.17 (1.04–1.32) | 0.0102 | |
| 5 | All-cause death | 1.11 (1.01–1.21) | 0.0323 | 0.98 (0.90–1.07) | 0.6516 |
| Major cardiovascular events | 1.09 (0.98–1.20) | 0.1077 | 1.00 (0.91–1.09) | 0.9688 | |
| New or worsening nephropathy | 1.32 (1.14–1.54) | 0.0003 | 1.20 (1.07–1.35) | 0.0015 | |
| 6 | All-cause death | 1.11 (1.01–1.22) | 0.0257 | 0.96 (0.88–1.06) | 0.4385 |
| Major cardiovascular events | 1.10 (0.99–1.22) | 0.0687 | 0.98 (0.89–1.08) | 0.7276 | |
| New or worsening nephropathy | 1.28 (1.10–1.49) | 0.0017 | 1.17 (1.04–1.32) | 0.0101 | |
| . | . | sRAGE (log scale) (per 1 unit*) . | Laboratory AGE value (per 100 RFU/mg protein*) . | ||
|---|---|---|---|---|---|
| Model . | Outcome . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| 1 | All-cause death | 1.20 (1.09–1.32) | 0.0002 | 1.05 (0.97–1.14) | 0.2193 |
| Major cardiovascular events | 1.16 (1.05–1.29) | 0.0038 | 1.06 (0.98–1.15) | 0.1262 | |
| New or worsening nephropathy | 1.43 (1.23–1.67) | <0.0001 | 1.25 (1.12–1.38) | <0.0001 | |
| 2 | All-cause death | 1.17 (1.06–1.29) | 0.0015 | 1.00 (0.91–1.09) | 0.9474 |
| Major cardiovascular events | 1.14 (1.02–1.26) | 0.0158 | 1.02 (0.93–1.11) | 0.7392 | |
| New or worsening nephropathy | 1.39 (1.19–1.63) | <0.0001 | 1.21 (1.08–1.35) | 0.0009 | |
| 3 | All-cause death | 1.11 (1.00–1.22) | 0.0451 | 0.97 (0.89–1.06) | 0.5382 |
| Major cardiovascular events | 1.08 (0.97–1.21) | 0.1471 | 1.02 (0.93–1.12) | 0.7121 | |
| New or worsening nephropathy | 1.20 (1.02–1.41) | 0.0316 | 1.21 (1.08–1.36) | 0.0013 | |
| 4 | All-cause death | 1.17 (1.06–1.29) | 0.0013 | 0.97 (0.89–1.06) | 0.5522 |
| Major cardiovascular events | 1.15 (1.03–1.27) | 0.0102 | 0.99 (0.91–1.09) | 0.8881 | |
| New or worsening nephropathy | 1.34 (1.15–1.57) | 0.0002 | 1.17 (1.04–1.32) | 0.0102 | |
| 5 | All-cause death | 1.11 (1.01–1.21) | 0.0323 | 0.98 (0.90–1.07) | 0.6516 |
| Major cardiovascular events | 1.09 (0.98–1.20) | 0.1077 | 1.00 (0.91–1.09) | 0.9688 | |
| New or worsening nephropathy | 1.32 (1.14–1.54) | 0.0003 | 1.20 (1.07–1.35) | 0.0015 | |
| 6 | All-cause death | 1.11 (1.01–1.22) | 0.0257 | 0.96 (0.88–1.06) | 0.4385 |
| Major cardiovascular events | 1.10 (0.99–1.22) | 0.0687 | 0.98 (0.89–1.08) | 0.7276 | |
| New or worsening nephropathy | 1.28 (1.10–1.49) | 0.0017 | 1.17 (1.04–1.32) | 0.0101 | |
Model 1: adjusted for age, sex, and randomized treatment groups; model 2: as model 1, but adjusted additionally for duration of diabetes, current smoking, systolic blood pressure, BMI, plasma glucose, HbA1c, total cholesterol, HDL cholesterol, triglycerides, and history of macrovascular events; model 3: as model 2, but additionally adjusted for ACR and eGFR (by the Chronic Kidney Disease Epidemiology Collaboration equation); model 4: as model 2, but adjusted additionally for sRAGE or AGE, as appropriate; model 5: as model 3, but adjusted additionally for hs-cTnT, NT-proBNP, hs-CRP, and use of β-blockers; model 6: as model 5, but additionally adjusted for sRAGE or AGE, as appropriate. *Approximately 1 SD (on the raw scale sRAGE was measured in pg/mL).